GRI 最新10-Q变化
将 GRI 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-14 与上一份 10-Q · 2026-05-13
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +18 | −12 | ~10 | 34 |
| 控制与程序 | 文字有新增/删除 | +2 | −1 | ~4 | 3 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 风险因素 | 部分风险因素更新 | +3 | 0 | ~1 | 0 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):市场风险(第3项)
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-14
Results from this Phase 2a trial are being used to determine safety sample size, clinically relevant endpoints and clinical trial duration in communication with the FDA in designing future trials. The Company recently requested a Type C meeting to discuss clinical study plans for the GRI-0621 IPF pr…
On June 18, 2026, the FDA granted Orphan Drug Designation to GRI-0621 for the treatment of IPF. Orphan Drug Designation is granted to therapies intended to treat rare diseases affecting fewer than 200,000 people in the United States and provides important development and commercialization benefits, …
Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T cells and would be developed for the treatment of autoimmune disorders, with much of o…
in a Phase 1a and 1b trial in healthy volunteers in the first half of 2027. We expect to continue to evaluate indications to select the best fit for further development of the program, but our initial focus would be on lupus.
On January 15, 2026, our stockholders approved the January 2026 Reverse Stock Split within a range of not less than one-for-two and not more than one-for-thirty, and our Board of Directors subsequently approved the January 2026 Reverse Stock Split at the ratio of one-for-twenty-eight. Following thes…
相对上期删除的文字 · 来源:10-Q · 2026-05-13
Final results from this trial will be used to determine dose, safety sample size, clinically relevant endpoints and clinical trial duration in communication with the FDA in designing future trials. Based on these results and subject to FDA clearance and obtaining the requisite additional funding or …
Our product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the lead molecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T cells and would be developed for the treatment of autoimmune disorders, with much of o…
On January 15, 2026, our stockholders approved the January 2026 Reverse Stock Split within a range of not less than one-for-two and not more than one-for-thirty, and our Board subsequently approved the January 2026 Reverse Stock Split at the ratio of one-for-twenty-eight. Following these approvals, …
Comparison of the Three Months Ended March 31, 2026 and 2025
Since inception, we have incurred losses and expect to continue to incur losses for the foreseeable future. We incurred net losses of $2.0 million and $3.0 million for the three months ended March 31, 2026 and 2025, respectively. As of March 31, 2026, we had an accumulated deficit of $53.7 million.
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-14
During the quarter ended June 30, 2026, management completed a redesign of the control environment to address the inherent limitations previously identified in connection with our accounting software, including enhancements to monitoring and review procedures and the reassignment of responsibilities…
transactions. In light of these actions, management does not currently expect to hire the additional accounting personnel as previously contemplated in our Annual Report in order to remediate the identified material weakness. However these revised controls must operate for a sufficient period of tim…
相对上期删除的文字 · 来源:10-Q · 2026-05-13
Subsequent to March 31, 2026, management initiated a redesign of the control environment to address the inherent limitations previously identified in connection with our accounting software, including enhancements to monitoring and review procedures and the reassignment of responsibilities to streng…
风险因素
相对上期新增的文字 · 来源:10-Q · 2026-08-14
The Nasdaq Stock Market LLC (Nasdaq) has adopted a new continued listing requirement that requires listed companies to maintain a Market Value of Listed Securities (MVLS) of at least $5 million, but the SEC has stayed approval of this requirement pending Commission-level review. If the requirement b…
On July 22, 2026, the SEC’s Division of Trading and Markets, acting under delegated authority, approved Nasdaq’s new MVLS continued listing requirement (the “MVLS Requirement”) requiring listed companies to maintain a Market Value of Listed Securities of at least $5 million. On July 29, 2026, the SE…
If the MVLS Requirement becomes effective and our Common Stock is suspended and delisted from The Nasdaq Capital Market, it would materially and adversely affect our ability to raise additional capital on acceptable terms, or at all, the liquidity and trading price of our Common Stock, our ability t…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议